Zonisamide and associated oligohidrosis and hyperthermia

Phillip Anson Low, Steven James, Tobias Peschel, Robert Leong, Adrienne Rothstein

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Zonisamide is an antiepileptic agent that is indicated as adjunctive therapy for the treatment of partial seizures in adults. Oligohidrosis has been reported in a small number of patients receiving zonisamide and, in a proportion of these patients, hyperthermia has occurred. Most reports of hyperthermia have been in children, typically occurring during the summer months. However, the mechanism of zonisamide-associated oligohidrosis is not fully understood. Thirteen events of oligohidrosis, or hyperthermia, associated with zonisamide were reported in the US during the 3 years after zonisamide was approved, an estimated incidence of 1 case per 4590 patient-years. These events happened mostly in children. In Japan, all reported cases of zonisamide-associated oligohidrosis or hyperthermia have been in children, with an incidence of 1 case per 10,000 pediatric-years during the first 11 years of marketing. In each case, oligohidrosis was reversible upon discontinuation of zonisamide. Ensuring that children remain cool and well hydrated during hot weather can minimize the potential for hyperthermia resulting from oligohidrosis.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalEpilepsy Research
Volume62
Issue number1
DOIs
StatePublished - Nov 2004

Fingerprint

zonisamide
Fever
Incidence
Weather
Marketing
Anticonvulsants

Keywords

  • Epilepsy
  • Fever
  • Hyperthermia
  • Hypohidrosis
  • Oligohidrosis
  • Zonegran
  • Zonisamide

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Zonisamide and associated oligohidrosis and hyperthermia. / Low, Phillip Anson; James, Steven; Peschel, Tobias; Leong, Robert; Rothstein, Adrienne.

In: Epilepsy Research, Vol. 62, No. 1, 11.2004, p. 27-34.

Research output: Contribution to journalArticle

Low, PA, James, S, Peschel, T, Leong, R & Rothstein, A 2004, 'Zonisamide and associated oligohidrosis and hyperthermia', Epilepsy Research, vol. 62, no. 1, pp. 27-34. https://doi.org/10.1016/j.eplepsyres.2004.06.009
Low, Phillip Anson ; James, Steven ; Peschel, Tobias ; Leong, Robert ; Rothstein, Adrienne. / Zonisamide and associated oligohidrosis and hyperthermia. In: Epilepsy Research. 2004 ; Vol. 62, No. 1. pp. 27-34.
@article{f4bd9d478323453297cacf6875252ba6,
title = "Zonisamide and associated oligohidrosis and hyperthermia",
abstract = "Zonisamide is an antiepileptic agent that is indicated as adjunctive therapy for the treatment of partial seizures in adults. Oligohidrosis has been reported in a small number of patients receiving zonisamide and, in a proportion of these patients, hyperthermia has occurred. Most reports of hyperthermia have been in children, typically occurring during the summer months. However, the mechanism of zonisamide-associated oligohidrosis is not fully understood. Thirteen events of oligohidrosis, or hyperthermia, associated with zonisamide were reported in the US during the 3 years after zonisamide was approved, an estimated incidence of 1 case per 4590 patient-years. These events happened mostly in children. In Japan, all reported cases of zonisamide-associated oligohidrosis or hyperthermia have been in children, with an incidence of 1 case per 10,000 pediatric-years during the first 11 years of marketing. In each case, oligohidrosis was reversible upon discontinuation of zonisamide. Ensuring that children remain cool and well hydrated during hot weather can minimize the potential for hyperthermia resulting from oligohidrosis.",
keywords = "Epilepsy, Fever, Hyperthermia, Hypohidrosis, Oligohidrosis, Zonegran, Zonisamide",
author = "Low, {Phillip Anson} and Steven James and Tobias Peschel and Robert Leong and Adrienne Rothstein",
year = "2004",
month = "11",
doi = "10.1016/j.eplepsyres.2004.06.009",
language = "English (US)",
volume = "62",
pages = "27--34",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Zonisamide and associated oligohidrosis and hyperthermia

AU - Low, Phillip Anson

AU - James, Steven

AU - Peschel, Tobias

AU - Leong, Robert

AU - Rothstein, Adrienne

PY - 2004/11

Y1 - 2004/11

N2 - Zonisamide is an antiepileptic agent that is indicated as adjunctive therapy for the treatment of partial seizures in adults. Oligohidrosis has been reported in a small number of patients receiving zonisamide and, in a proportion of these patients, hyperthermia has occurred. Most reports of hyperthermia have been in children, typically occurring during the summer months. However, the mechanism of zonisamide-associated oligohidrosis is not fully understood. Thirteen events of oligohidrosis, or hyperthermia, associated with zonisamide were reported in the US during the 3 years after zonisamide was approved, an estimated incidence of 1 case per 4590 patient-years. These events happened mostly in children. In Japan, all reported cases of zonisamide-associated oligohidrosis or hyperthermia have been in children, with an incidence of 1 case per 10,000 pediatric-years during the first 11 years of marketing. In each case, oligohidrosis was reversible upon discontinuation of zonisamide. Ensuring that children remain cool and well hydrated during hot weather can minimize the potential for hyperthermia resulting from oligohidrosis.

AB - Zonisamide is an antiepileptic agent that is indicated as adjunctive therapy for the treatment of partial seizures in adults. Oligohidrosis has been reported in a small number of patients receiving zonisamide and, in a proportion of these patients, hyperthermia has occurred. Most reports of hyperthermia have been in children, typically occurring during the summer months. However, the mechanism of zonisamide-associated oligohidrosis is not fully understood. Thirteen events of oligohidrosis, or hyperthermia, associated with zonisamide were reported in the US during the 3 years after zonisamide was approved, an estimated incidence of 1 case per 4590 patient-years. These events happened mostly in children. In Japan, all reported cases of zonisamide-associated oligohidrosis or hyperthermia have been in children, with an incidence of 1 case per 10,000 pediatric-years during the first 11 years of marketing. In each case, oligohidrosis was reversible upon discontinuation of zonisamide. Ensuring that children remain cool and well hydrated during hot weather can minimize the potential for hyperthermia resulting from oligohidrosis.

KW - Epilepsy

KW - Fever

KW - Hyperthermia

KW - Hypohidrosis

KW - Oligohidrosis

KW - Zonegran

KW - Zonisamide

UR - http://www.scopus.com/inward/record.url?scp=7044240924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044240924&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2004.06.009

DO - 10.1016/j.eplepsyres.2004.06.009

M3 - Article

C2 - 15519129

AN - SCOPUS:7044240924

VL - 62

SP - 27

EP - 34

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -